Ionis director granted RSUs and stock options
IONIS PHARMACEUTICALS INC director Joseph Loscalzo received equity awards as part of non-employee director compensation.
Rhea-AI Filing Summary
IONIS PHARMACEUTICALS INC director Joseph Loscalzo received equity awards as part of non-employee director compensation. On July 1, 2026, he was granted 2,301 Restricted Stock Units, each representing one share of common stock or its cash equivalent, bringing his RSU-related holdings to 7,521 units.
He was also granted 5,369 Non-Qualified Stock Options with an exercise price of $79.19 per share. Both the RSUs and options vest 100% on the earlier of the first anniversary of grant or the next annual stockholders’ meeting, with RSUs delivered on the July 15 following vesting. The company’s Non-Employee Director Compensation Policy caps his 2026 annual equity compensation at $400,000 based on grant date fair value under FASB Topic ASC 718.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 7,670 shares
Grant/Award
2 txns
Insider
LOSCALZO JOSEPH
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 5,369 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 2,301 | $0.00 | $0.00 |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 5,369 contracts (Direct);
Restricted Stock Unit — 7,521 contracts (Direct)
Footnotes (4)
- F1. Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.
- F2. Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026.
- F3. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- F4. Grant on July 1, 2026 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2026.
Key Figures
RSU grant: 2,301 units
RSUs after grant: 7,521 units
Stock option grant: 5,369 options
+3 more
6 metrics
RSU grant
2,301 units
Restricted Stock Units granted on July 1, 2026
RSUs after grant
7,521 units
Total RSU-related holding following transaction
Stock option grant
5,369 options
Non-Qualified Stock Options granted on July 1, 2026
Option exercise price
$79.19 per share
Exercise price for new Non-Qualified Stock Options
Option expiration
June 30, 2036
Expiration date of granted stock options
Equity comp cap 2026
$400,000
Maximum 2026 annual equity compensation grant-date fair value
Key Terms
Restricted Stock Unit, Non-Qualified Stock Option, Non-Employee Director Compensation Policy, grant date fair value, +1 more
5 terms
Restricted Stock Unit financial
"Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Non-Qualified Stock Option financial
"Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan."
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Non-Employee Director Compensation Policy financial
"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000."
grant date fair value financial
"annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."
The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.
FASB Topic ASC 718 financial
"based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."
FAQ
What equity awards did Ionis (IONS) director Joseph Loscalzo receive?
Joseph Loscalzo received 2,301 Restricted Stock Units and 5,369 Non-Qualified Stock Options on July 1, 2026. The RSUs convert into common stock or cash, while the options allow future share purchases at a fixed exercise price of $79.19.
How and when do Joseph Loscalzo’s new Ionis (IONS) RSUs vest?
The 2,301 Restricted Stock Units vest 100% on the earlier of the first anniversary of the July 1, 2026 grant or the next annual stockholders’ meeting. After vesting, the RSUs are delivered on the July 15 immediately following the vesting date.
What are the key terms of Joseph Loscalzo’s new Ionis stock options?
Loscalzo received 5,369 Non-Qualified Stock Options with a $79.19 exercise price. All shares under the option vest and become exercisable on the earlier of the first anniversary of grant or the next annual stockholders’ meeting, and expire on June 30, 2036.
How is Ionis (IONS) limiting Joseph Loscalzo’s 2026 director equity compensation?
Ionis adjusted these grants so his 2026 annual equity compensation does not exceed $400,000 in aggregate grant date fair value. The cap is set by the company’s Non-Employee Director Compensation Policy and calculated under FASB Topic ASC 718 accounting rules.
Under which plan were Joseph Loscalzo’s Ionis (IONS) awards granted?
Both the stock options and Restricted Stock Units were granted under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. This plan governs equity compensation for non-employee directors, including vesting schedules and delivery mechanics for awards.
When are Joseph Loscalzo’s new Ionis (IONS) options exercisable?
The options are exercisable as to 0 shares on July 1, 2026 and vest fully later. All 5,369 shares under the option become exercisable on the earlier of the first anniversary of grant or the next regularly scheduled annual stockholders’ meeting, then remain exercisable until June 30, 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
